US 12,168,055 B2
Sonosensitization
Stuart L. Marcus, Berkeley, CA (US)
Assigned to SonalaSense, Inc., Berkeley, CA (US)
Filed by SONALASENSE, INC., Berkeley, CA (US)
Filed on Feb. 22, 2024, as Appl. No. 18/584,620.
Application 18/584,620 is a continuation of application No. 17/613,788, previously published as PCT/US2020/034944, filed on May 28, 2020.
Claims priority of provisional application 62/853,853, filed on May 29, 2019.
Prior Publication US 2024/0189427 A1, Jun. 13, 2024
Int. Cl. A61K 41/00 (2020.01); A61K 9/00 (2006.01); A61K 31/197 (2006.01); A61M 37/00 (2006.01); A61N 7/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 41/0033 (2013.01) [A61K 9/0019 (2013.01); A61K 31/197 (2013.01); A61M 37/0092 (2013.01); A61N 7/00 (2013.01); A61P 35/00 (2018.01); A61M 2205/6054 (2013.01); A61N 2007/0039 (2013.01)] 29 Claims
OG exemplary drawing
 
1. A method for treating diffuse intrinsic pontine glioma in a human subject in need thereof, the method comprising:
a) intravenously administering from 5 mg/kg to 750 mg/kg of gamma-irradiated 5-aminolevulinic acid (5-ALA), or a pharmaceutically acceptable salt thereof, to the subject; and
b) exposing diffuse intrinsic pontine glioma tissue in the subject to ultrasound energy by sonicating the tissue at a plurality of individual points using a focused ultrasound (FUS) device at a frequency of about 0.1 MHz to about 3 MHz and an intensity at an ultrasound beam focus of about 3 W/cm2 to about 100 W/cm2.